Literature DB >> 36190267

Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro.

Saurav Howlader1,2, Min-Jung Kim1,2,3, M Rasheduzzaman Jony1,2, Nguyen Phuoc Long1,2, Yong-Soon Cho1,2, Dong-Hyun Kim1,2, Jae-Gook Shin1,2,3,4.   

Abstract

Clofazimine [N,5-bis(4-chlorophenyl)-3-[(propane-2-yl)rimino]-3,5-dihydrophenazin-2-amine] is an antimycobacterial agent used as a second-line antituberculosis (anti-TB) drug. Nonetheless, little information is known about the metabolic routes of clofazimine, and the enzymes involved in metabolism. This study aimed to characterize the metabolic pathways and enzymes responsible for the metabolism of clofazimine in human liver microsomes. Eight metabolites, including four oxidative metabolites, three glucuronide conjugates, and one sulfate conjugate were identified, and their structures were deduced based on tandem mass spectrometry (MS/MS) spectra. Hydroxylated clofazimine and hydrated clofazimine was generated even in the absence of the NADPH generating system presumably via a nonenzymatic pathway. Hydrolytic-dehalogenated clofazimine was catalyzed mainly by CYP1A2 whereas hydrolytic-deaminated clofazimine was formed by CYP3A4/A5. In case of glucuronide conjugates, UGT1A1, UGT1A3, and UGT1A9 showed catalytic activity toward hydroxylated and hydrated clofazimine glucuronide whereas hydrolytic-deaminated clofazimine glucuronide was catalyzed by UGT1A4, UGT1A9, UGT1A3, and UGT2B4. Our results suggested that CYP1A2 and CYP3A are involved in the formation of oxidative metabolites while UGT1A1, 1A3, 1A4, 1A9, and 2B4 are involved in the formation of glucuronide conjugates of oxidative metabolites of clofazimine.

Entities:  

Keywords:  LC-MS/MS; UDP-glucuronosyltransferase; clofazimine; cytochrome P450; metabolism

Mesh:

Substances:

Year:  2022        PMID: 36190267      PMCID: PMC9578437          DOI: 10.1128/aac.00565-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  34 in total

1.  In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.

Authors:  N H Schebb; B Franze; R Maul; A Ranganathan; B D Hammock
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

2.  High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.

Authors:  Min-Jung Kim; Hyojin Kim; In-June Cha; Jang-Su Park; Ji-Hong Shon; Kwang-Hyeon Liu; Jae-Gook Shin
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

Review 3.  Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.

Authors:  Swati Nagar; Rebecca L Blanchard
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

4.  Characterization of clofazimine metabolites in humans by HPLC-electrospray mass spectrometry.

Authors:  D R Krishna; R N Mamidi; U Hofmann; C M Prabhakar
Journal:  Arzneimittelforschung       Date:  1997-03

5.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

6.  Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.

Authors:  L Iyer; D Hall; S Das; M A Mortell; J Ramírez; S Kim; A Di Rienzo; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

7.  Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004.

Authors:  Henriette Kold Uldam; Martin Juhl; Henrik Pedersen; Lars Dalgaard
Journal:  Drug Metab Dispos       Date:  2011-09-06       Impact factor: 3.922

8.  Metabolism of clofazimine in leprosy patients.

Authors:  P C Feng; C C Fenselau; R R Jacobson
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

Review 9.  Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence.

Authors:  Issar Smith
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 10.  UGT1A1 Mediated Drug Interactions and its Clinical Relevance.

Authors:  Chong Ping Goon; Ling Zhi Wang; Fang Cheng Wong; Win Lwin Thuya; Paul Chi-Lui Ho; Boon Cher Goh
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.